Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893765 | 1.00 | EPHX2 (0.43) | EPHX2KMT2ACASP3CYP3A4CYP2C19 | |
| SCHEMBL3026489 | 0.86 | EPHX2 (0.57) | EPHX2KMT2ACASP3RAB9AMAPT | |
| SCHEMBL3026492 | 0.86 | EPHX2 (0.57) | EPHX2KMT2ACASP3RAB9AMAPT | |
| SCHEMBL30946961 | 0.86 | EPHX2 (0.57) | EPHX2KMT2ACASP3RAB9AMAPT | |
| SCHEMBL879811 | 0.77 | EPHX2 (0.49) | EPHX2KMT2ACYP3A4CYP2C19RAB9A | |
| SCHEMBL29503775 | 0.77 | KMT2A (0.54) | EPHX2KMT2ACASP3MDM4TP53 | |
| SCHEMBL29362505 | 0.77 | KMT2A (0.54) | EPHX2KMT2ACASP3MDM4TP53 | |
| SCHEMBL119779 | 0.77 | KMT2A (0.54) | EPHX2KMT2ACASP3MDM4TP53 | |
| SCHEMBL15341324 | 0.76 | KMT2A (0.51) | EPHX2KMT2ACASP3 | |
| SCHEMBL27443155 | 0.76 | KMT2A (0.56) | EPHX2KMT2ACASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | EPHX2 1731/4885KMT2A 3406/4885CASP3 760/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | EPHX2 3066/4885KMT2A 1805/4885CASP3 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.